title: Amphotericin B intralipid formulation: stability and particle size.
abstract: Amphotericin B remains the drug of choice for treating systemic fungal infections, although toxicity limits its clinical use. Some studies reported the use of Intralipid deoxycholate amphotericin B as an alternative delivery system. An in-vitro study was performed to assess the compatibility of deoxycholate amphotericin B in Intralipid. With two types of dilution of deoxycholate amphotericin B (in 5% dextrose and Intralipid or in Intralipid alone) the solution stability was not constant with a clear yellow precipitate. We observed an increase in the size of the particles (1.5-4-fold). In light of these results Intralipid deoxycholate amphotericin B should not be routinely administered.
authors.affiliation: Department of Anesthesiology, Cancer Center Léon Bérard, Lyon, France.
authors.forename: J Y
authors.initials: JY
authors.lastname: Ranchère
authors.forename: J F
authors.initials: JF
authors.lastname: Latour
authors.forename: C
authors.initials: C
authors.lastname: Fuhrmann
authors.forename: C
authors.initials: C
authors.lastname: Lagallarde
authors.forename: F
authors.initials: F
authors.lastname: Loreuil
mesh_terms: D000666:Amphotericin B / Q000737:chemistry*; D000900:Anti-Bacterial Agents / Q000737:chemistry; D000935:Antifungal Agents / Q000737:chemistry; D011232:Chemical Precipitation; D004355:Drug Stability; D005217:Fat Emulsions, Intravenous / Q000737:chemistry*; D009994:Osmolar Concentration; D013594:Syringes; D013997:Time Factors
chemical_list: D000900:Anti-Bacterial Agents; D000935:Antifungal Agents; D005217:Fat Emulsions, Intravenous; D000666:Amphotericin B